X-Rx Overview
- Founded
- 2012
- Status
- Out of Business
- Latest Deal Type
- Out of Business
X-Rx General Information
Description
Developer of a drug discovery platform intended to offer advanced small molecule medicines in inflammation, fibrosis, and oncology. The company's platform combines the power of DNA-encoded libraries with a virtual development model to discover novel therapeutics for difficult to treat diseases, enabling doctors to identify tractable blood cells.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 100 Beaver Street
- Waltham, MA 02453
- United States
X-Rx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 01-Sep-2018 | 00.00 | Completed | Out of Business | ||
| 1. Early Stage VC (Series A) | 04-Jan-2013 | 00.00 | 00.00 | 000.00 | Completed | Startup |
X-Rx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 000 |